Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Genitourinary Cancer

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CGC.2008.s.002PMID 19891124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC)after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study

  2008cited by this paper
• Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

  2007cited by this paper
• Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

  2007cited by this paper
• 4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a

  2007cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC).

  2006cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

  2005cited by this paper
• Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

  2005cited by this paper
• Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.

  2005cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

  2004cited by this paper
• SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

  2003cited by this paper
• Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

  2003cited by this paper
• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  2003cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

  2000cited by this paper
• Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

  2000cited by this paper
• Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

  1999cited by this paper
• Standard of care.

  1998cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model.

  1985cited by this paper

• Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study

  2022cites this paper
• The CCL20-CCR6 Axis in Cancer Progression

  2020cites this paper
• Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma

  2019cites this paper
• An important step in establishing a treatment strategy for small renal masses of clear cell renal cell carcinoma based on the significance of adverse histopathologic features on tumor needle biopsy.

  2019cites this paper
• Tumor-Associated Macrophages Induce Migration of Renal Cell Carcinoma Cells via Activation of the CCL20-CCR6 Axis

  2019cites this paper
• A COMPLETE RESPONSE OF METASTATIC RENAL CELL CARCINOMA TO BEVACIZUMAB AND INTERFERON AFTER A NEPHRECTOMY : CASE REPORT

  2018cites this paper
• Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma.

  2016cites this paper
• Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

  2016cites this paper
• Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?

  2015cites this paper
• Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.

  2015cites this paper
• Downregulation of the tumor suppressor HSPB7, involved in the p53 pathway, in renal cell carcinoma by hypermethylation

  2014cites this paper
• Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma

  2014cites this paper
• Clinicopathological characteristics and prognosis of patients according to recurrence time after radical nephrectomy for localized renal cell carcinoma: a multicenter study of Anatolian Society of Medical Oncology (ASMO).

  2014cites this paper
• Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.

  2014cites this paper
• Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma.

  2013cites this paper
• Systemic treatment options for untreated patients with metastatic clear cell renal cancer.

  2013cites this paper
• Estudo da deleção do cromossomo 9p como fator prognóstico no carcinoma renal tipo células claras localizado

  2013cites this paper
• Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.

  2013cites this paper
• New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma

  2012cites this paper
• Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma

  2012cites this paper
• Gene expression and protein array studies of folliculin-regulated pathways.

  2012cites this paper
• Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma

  2012cites this paper
• Three‐dimensional tumour volume and cancer‐specific survival for patients undergoing nephrectomy to treat pT1 clear‐cell renal cell carcinoma

  2012cites this paper
• Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.

  2012cites this paper
• Preclinical Development Therapeutic Targeting the Loss of the Birt-Hogg-Dub e Suppressor Gene

  2011cites this paper
• Pancreatic Metastasis from Renal Cell Carcinoma

  2011cites this paper
• Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non‐Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation

  2011cites this paper
• Suppressor Gene Therapeutic Targeting the Loss of the Birt-Hogg-Dubé

  2011cites this paper
• Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

  2011cites this paper
• Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib.

  2011cites this paper
• Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

  2011cites this paper
• Therapeutic Targeting the Loss of the Birt-Hogg-Dubé Suppressor Gene

  2011cites this paper
• Bevacizumab in Combination with Interferon Alpha in Metastatic Renal Cell Carcinoma: The Emerging Evidence of Its Therapeutic Value

  2011cites this paper
• Kidney Cancer Working Group report.

  2010cites this paper
• FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.

  2010cites this paper
• Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1

  2010influential citation
• Sarcomatoid chromophobe renal cell carcinoma: Cytohistopathological correlation of a case

  2010cites this paper
• Alterations in VHL as potential biomarkers in renal-cell carcinoma

  2010cites this paper
• Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.

  2010cites this paper
• Current Perspectives in Metastatic Renal Cell Carcinoma Treatment: The Role of Mammalian Target of Rapamycin (mTOR) Inhibition

  2009cites this paper
• Review of guidelines on the treatment of metastatic renal cell carcinoma

  2009cites this paper